inhibited IL-5 and IL-13 production by ILC2s in the presence of IL-25 or IL-33 (P 5 .031) and allergen-driven T H 2 cytokines by effector T cells. IL-35 inhibited CD40 ligand-, IL-4-, and IL-21-mediated IgE production by B cells (P 5 .015), allergen-driven T-cell proliferation (P 5 .001), and T H 2 cytokine production mediated by primed dendritic cells. iT R 35 cells suppressed T H 2 cell proliferation and cytokine production. In addition, allergen-driven IL-35 levels and iT R 35 cell counts were increased in patients receiving SLIT (all, P < .001) and NACs (all, P < .001) compared with patients with SAR. Conclusion: IL-35 and iT R Allergic rhinitis is a major health epidemic affecting up to 40% of the global population worldwide. 1, 2 It is characterized by inflammation of the lining of the nasal mucosa and clinical symptoms, such as runny and itchy nose, sneezing, nasal congestion, and red and watery eyes. [3] [4] [5] Symptomatic treatment, such as antihistamines and corticosteroids, are effective in most but not all patients. 6 Allergen immunotherapy (AIT), a disease-modifying treatment, administered as either the sublingual immunotherapy (SLIT) or subcutaneous immunotherapy, is effective in patients who are unresponsive to conventional pharmacotherapy. 6 AIT confers long-term clinical benefits through induction of immune tolerance to the sensitized allergen. [7] [8] [9] It has been well established that CD4
1

CD25
2 effector T (Teff) cells grouped into T H 2 and T H 17 cells contribute toward the pathophysiology of allergic response to the sensitizing allergen. 10 Numbers of regulatory T (Treg) cells, such as forkhead box protein 3 (FoxP3)
1 Treg cells, have been shown to be induced after AIT and have the capacity to suppress allergic inflammation by inhibiting the expansion and function of CD4 
2 Teff cells to maintain tolerance to allergens. 11, 12 IL-35 is a newly identified inhibitory cytokine produced by Treg cells that can elicit a suppressive immune response. 13 IL-35 is a member of the IL-12 family of heterodimeric cytokines (IL-12, IL-23, and IL-27) produced mainly by CD4 1 Foxp3
2
Treg cells, B cells, endothelial cells, smooth muscle cells, and monocytes. The heterodimeric cytokine is composed of an a-chain (p19, p28, or p35) and a b-chain (p40 or EBV-induced 3 [Ebi3]). The p35 subunit pairs with the Ebi3 subunit to form IL-35 and mediate signaling by binding to the IL-12 receptor b2/glycoprotein 130, activating the signal transducer and activator of transcription (STAT) 1 and STAT4 pathway. 14, 15 However, in contrast to the IL-12 family involved in the proinflammatory response, IL-35 mediates immunologic functions by suppressing the inflammatory immune response. It has also been reported that IL-35 can significantly reduce airway inflammation induced by allergen-specific T H 2 cells and reverse IL-17-dependent allergic disease in mice. 16, 17 Additionally, allergic asthmatic patients have shown reduced IL-35 protein and mRNA levels and reduced frequencies of CD4 
METHODS Subjects
Patients receiving grass pollen SLIT (n 5 16; Grazax; ALK-Abell o, Hørsholm, Denmark), untreated allergic subjects with seasonal rhinoconjunctivitis (SAR; n 5 16), and nonatopic control subjects (NACs; n 5 16) were recruited and completed symptom questionnaires (Table I and see Fig E1 in this article's Online Repository at www.jacionline.org). SLIT-treated patients had been receiving immunotherapy (Grazax tablet, 75,000 SQ-U, once daily) for 12 months to 3 years. Inclusion and exclusion criteria are described in the Methods section in this article's Online Repository at www.jacionline. org). Blood samples from participants (n 5 48) were collected during the grass pollen season. The study complied with Good Clinical Practice and was approved by the South West London REC3 Research Ethics Committee and the Research Office of Royal Brompton and Harefield NHS Foundation Trust. Written informed consent was obtained from all participants.
Rhinoconjunctivitis symptom scores
Participants were asked to complete a retrospective symptom questionnaire to assess the severity of their allergic rhinitis symptoms for the relevant pollen season. This included 6 categories of runny nose, blocked nose, itchy nose, sneezing, watery eyes, and itchy eyes. Each category was rated between 0 (no problem) and 3 (severe problems), resulting in a possible total score of 0 to 18 (Rhinoconjunctivitis Total Symptom Score [RTSS]). Participants were asked to evaluate their symptoms when their allergic rhinitis was at its most severe during the pollen season. 
Generation of iT R 35 cells
Naive T cells were isolated from PBMCs by using EasySep magnetic separation (STEMCELL Technologies) and stimulated with anti-CD3 and anti-CD28 (both at 1 mg/mL; R&D Systems) in the presence of 10 ng/mL IL-35 for 9 days at 378C in a 5% CO 2 atmosphere to generate the iT R 35 cell lineage. 20 iT R 35 cells were cocultured at a 1:1:1 ratio with CD4 1 (or memory)
T cells and irradiated APCs in the presence of 3 mg/mL P pratense for 7 days at 378C in a 5% CO 2 atmosphere. Where indicated, the neutralizing antibodies anti-IL-10 (10 mg/mL; BioLegend, London, United Kingdom), anti-TGF-b (10 mg/mL; R&D Systems), and anti-IL-35 (10 mg/mL) were added to the culture. Proliferation of memory T cells was assessed through incorporation of tritiated thymidine. T H 2 cytokine levels were measured in cell-culture supernatants by using the MagPix Milliplex Kit (EMD Millipore, Watford, United Kingdom) based on the manufacturer's protocol. 
Suppression of IgE by IL-35 in PBMCs of allergic patients
B cells were isolated from PBMCs by using negative isolation (Dynal Biotech, Oslo, Norway). Cells (0.5-50 3 10 3 /0.2 mL) were cultured with CD40 ligand (CD40L; 100 ng/mL) alone or with IL-4 (100 U/mL; both from R&D Systems) or IL-4 plus IL-21 (100 ng/mL; BioLegend). Cells were harvested after 14 days and cultured again (10-20 3 10 3 /0.2 mL) for 2 days with CD40L or CD40L plus IL-4. IgE was detected with ImmunoCAP, according to the manufacturer's protocol. IL-35 (10 ng/mL) was used to determine suppression of IgE production.
DCs: Naive T-cell coculture assays DCs (5 3 10 3 cells/well) were primed with TSLP (15 ng/mL), IL-25 (10 ng/mL), and IL-33 (10 ng/mL) for 24 hours. Primed DCs were then washed and cocultured with naive T cells (5 3 10 4 cells/well) and P pratense (5 mg/mL) in the presence or absence of IL-35 (10 ng/mL) at 378C in a 5% CO 2 atmosphere. Cell-culture supernatants were collected on day 9, and grass pollen2driven T-cell proliferation was measured by determining tritiated thymidine incorporation (MP Biomedicals, Costa Mesa, Calif).
iT R 35 cell and IL-35 production in patients receiving SLIT, patients with SAR, and NACs
PBMCs from the SLIT, SAR, and NAC groups were stimulated with phorbol 12-myristate 13-acetate/ionomycin for 6 hours, permeabilized, and subjected to intracellular staining with anti-human IL-12p35 and anti-human EBI3 antibodies. Dual IL-12p35 ). Furthermore, PBMCs from patients receiving SLIT, patients with SAR, and NACs were stimulated with grass pollen allergen for 6 days. IL-35 levels in cell-culture supernatants were measured by using ELISA (Cusabio Biotech, Wuhan, China), according to the manufacturer's instructions. 22, 23 Total and specific IgE
Total and timothy grass2specific IgE levels were quantified by using the ImmunoCAP FEIA system, according to the manufacturer's recommendations (Pharmacia, Uppsala, Sweden).
Statistics
Between-group comparisons were performed by using the Mann-Whitney U test, and within-group comparisons were performed by using the Wilcoxon Distribution of age, sex, specific IgE levels, and sensitization profile. *P < .01, comparison between the NAC and SAR groups. There were no significant differences for any other parameters among the 3 groups.
J ALLERGY CLIN IMMUNOL VOLUME 143, NUMBER 3 matched-pairs signed-rank test. Correlation analysis was determined by using the Spearman rank method. The statistical software package used was GraphPad Prism (version 5; GraphPad Software, La Jolla, Calif). A P value of less than .05 was considered significant.
RESULTS
Enumeration of ILC2s in patients with grass pollen allergy and NACs
To examine the biological effect of IL-35 13, 15, 20 on ILC2s (Lin
1 ), which have previously been shown to have a role in type II allergic inflammation, [24] [25] [26] we enumerated ILC2s in peripheral blood of patients with moderate-to-severe SAR. During the pollen season, proportions of ILC2s were greater in patients with SAR compared with those in NACs (P 5 .002; Fig 1, A and B) . Similarly, IL-5
1 , IL-13
1
, and dual IL-5
proportions were increased in patients with SAR compared with NACs (P 5 .042, P 5 .042, and P 5 .003; Fig 1, C) , supporting a pathophysiologic role for ILC2s in patients with SAR during natural grass pollen allergen exposure. We then assessed whether IL-35 would inhibit IL-5 and IL-13 production by ILC2s. IL-5 and IL-13 production by ILC2s was significantly reduced by IL-35 (all P 5 .031; Fig 1, E and F) .
IL-35 suppressed, allergen-driven Teff cell proliferation
The effect of IL-35 on allergen-specific memory/effector T H 2 cells in allergic patients with SAR was investigated. Teff cells (CD4
1
CD25
2 cells) were cocultured with APCs and stimulated with grass pollen allergen (P pratense) in the presence of IL-35. Allergen-driven Teff cell proliferation was suppressed in an IL-35 dose-dependent manner (optimal at 10 ng/mL, P 5 .0001) but not when exposed to blocking anti-IL-35 mAbs (Fig 2, A) . Allergen-specific T cells produce IL-4, IL-5, IL-13 (T H 2 cytokines), and IL-17 (T H 17 cytokine), which contribute to allergic rhinitis. 27 IL-35 suppressed allergen-driven production of IL-4 (P < .0001), IL-5 (P < .0001), IL-9 (P < .0001), IL-13 (P < .009), and IL-17 (P < .0001) by Teff cells (Fig 2, B) . Interestingly, IL-35 induced expression of IFN-g (P 5 .004) and IL-10 (P < .0002) by Teff cells (Fig 2, C) . The effects of IL-35 were specific because the C-peptide linker used for its IL-5 and IL-13 levels are shown. P values were determined by using the Mann-Whitney U test or Wilcoxon matched-pairs signed-rank test: *P < .05 and **P < .001.
expression had no effect on either Teff cell proliferation or cytokine production (see Fig E2 in this article's Online Repository at www.jacionline.org). In addition to this, the effect of IL-35 on in vitro-generated T H 1 and T H 2 clones was also investigated. 27 IL-35 significantly reduced T H 2 clone proliferation (P 5 .0001; Fig 2, D) , as well as IL-5 (P 5 .0001) and IL-13 (P < .02) gene expression (Fig 2, E) . T H 2 transcription factor GATA3 mRNA expression was decreased by IL-35 (P 5 .039; Fig 2, F) . Proliferation of T H 1 clones was also suppressed, although to a lesser magnitude (P 5 .003; Fig 2, G) . However, in the presence of IL-35, level of IFN-g production by T H 1 clones was unaffected, whereas T-bet mRNA expression was upregulated (P 5 .041; Fig 2, G-I ).
IL-35-treated Teff cells inhibit grass pollen-driven T H 2 effector cell responses
Prior treatment of Teff cells with IL-35 imparted a suppressive phenotype in coculture experiments with untreated allergen-specific Teff cells (Fig 3) . This suppression was optimal at 2:1 (IL-35-treated Teff cells/untreated Teff cells) and still persisted at 64:1. Anti-IL-35-neutralizing mAb reversed this inhibition in a dose-dependent manner (Fig 3, A) . Furthermore, IL-35-treated Teff cells suppressed allergen-induced IL-4 (P 5 .0004), IL-5 (P 5 .0004), IL-13 (P 5 .0001), and IL-17 (P 5 .0004) production by Teff cells, which was also reversed by anti-IL-35-neutralizing antibody (Fig 3, B) . 1 CD25 2 T cells were cocultured with APCs and stimulated with P pratense allergen in the presence of IL-35. Proliferation was assessed by using tritiated thymidine incorporation. B and C, Effect of IL-35 on allergen-driven production of T H 2 cytokines (Fig 2, B) and T H 1 cytokines and IL-10 (Fig 2, C) . D-F, Effects of IL-35 were also assessed on T H 2 clone proliferation (Fig 2, D) ; IL5, IL13, and IFNG mRNA expression (Fig 2, E) , and GATA3 expression (Fig 2, F) . G-I, Effects of IL-35 on T H 1 clone proliferation (Fig 2, G) , cytokine production (Fig 2, H) , and T-bet mRNA expression (Fig 2, I ) were assessed. P values were determined by using the Wilcoxon matched-pairs signed-rank test: *P < .05, **P < .001, and ***P < .0001.
IL-35 induced generation of iT R 35 cells with the ability to suppress T H 2 cytokine production
Murine studies have shown that IL-35 can convert Teff cells into iT R 35 cells. 13, 20, 27, 28 Therefore we assessed whether human IL-35 could polarize human CD4 1 CD45RA 1 (naive) T cells into iT R 35 cells. Naive T cells obtained from patients with SAR were exposed to IL-35 and stimulated with anti-CD3/CD28 mAbs for 9 days. This resulted in induction of IL12A (P 5 .0005) and Ebi3 (P 5 .0005) gene expression (Fig 4, A) and production of iT R 35 cells (P 5 .0005; Fig 4, B) . These iT R 35 cells suppressed allergen-driven CD4
1
CD45RO
1 memory T cells in an IL-35-and IL-10-dependent manner (Fig 4, C and D) . The iT R 35 cells also suppressed IL-4 (P 5 .004), IL-5 (P 5 .004), and IL-13 (P 5 .001) production by memory T H 2 cells (Fig 4, E) . Furthermore, we confirmed that IL-35 exerted its effects on human Teff cells by signaling through STAT1 and STAT4 after T-cell receptor stimulation (Fig 4, F) .
IL-35 inhibits production of allergen-specific IgE by B cells
T H 2 cytokines drive isotype class-switching of B cells toward IgE antibody production. [29] [30] [31] [32] IL-21 and IL-4 act synergistically on B cells to facilitate IgE secretion (P 5 .002; Fig 5, A and  B) , 33, 34 which binds to FcεRI on mast cells and basophils in the nasal mucosa. Subsequent cross-linking by allergen results in release of the histamine and lipid mediators that are responsible for allergy symptoms. 32 We investigated whether IL-35 can counteract the effects of IL-4 and IL-21 and inhibit IgE production by B cells. IL-35 suppressed IgE production by allergen-specific PBMCs after costimulation with CD40L, IL-4, and IL-21 (P 5 .015; Fig 5, C) . This suppression was reversed by neutralizing IL-35 antibodies in a dose-dependent manner (P 5 .031; Fig 5, C) . Therefore, in addition to exerting effects on T H 2 responses, IL-35 inhibited allergen-specific IgE production.
IL-35 inhibits TSLP-induced naive T-cell activation and differentiation into T H 2 cells
Recent evidence has implicated TSLP in the DC priming of T H 2 responses in asthmatic patients. 35 On stimulation with P pratense, TSLP-primed DCs were able to induce significantly greater proliferation of naive T cells when compared with non-TSLP-primed DCs (P 5 .001; Fig 6, A) . In contrast to this, IL-25-and IL-33-primed DCs did not affect the proliferation of naive T cells (Fig 6, A) . The increase in TSLP-induced, allergen-driven naive T-cell proliferative response was accompanied by an increase in IL-5 (P 5 .004; Fig 6, B) and IL-13 (P 5 .004; Fig 6, C) production. In parallel to this, the effect of IL-35 on TSLP priming of specific T H 2 cells by DCs from patients with grass pollen allergy was investigated. were measured. P values were determined by using the Wilcoxon matched-pairs signed-rank test: *P < .05, **P < .001, and ***P < .0001. 
Enumeration of iT R 35 cells in patients receiving AIT, patients with SAR, and NACs
SLIT-treated subjects had significantly reduced rhinitis symptom scores compared with patients with SAR (Fig 7, A) . We measured numbers of peripheral blood iT R 35 cells in patients who had received a course of SLIT for severe allergic rhinitis (Fig 7, B and C) . SLIT-treated patients had increased numbers of iT R 35 cells (P < .001) compared with patients with untreated SAR, and no difference was observed when compared with NACs (Fig 7, B and C) . Ex vivo stimulation revealed increased levels of IL-35 from SLIT-treated patients (P < .001) and NACs (P < .001) compared with patients with untreated SAR (Fig 7, D) . A positive correlation between IL-35 levels and proportion of IL-35
1 Treg cells was observed (Fig 7, E) . For all participants, both the proportion of IL-35
1 Treg cells and the levels of IL-35 in culture supernatants inversely correlated with clinical symptoms (Fig 7, F and G) and for IL-35; this was also significant within the SLIT-treated group alone.
DISCUSSION
For the first time, we report that IL-35 production by iT R Several studies have shown that ILC2s primed with epithelium-derived mediators, such as IL-33, 36 IL-25, 37 TSLP, 38 and leukotriene D 4 , induce type 2 allergic inflammation and tissue repair. 39 The involvement of ILC2s in the pathogenesis of allergic rhinitis was first demonstrated in subjects undergoing intranasal cat allergen provocation, which led to an increased percentage of ILC2s after 4 hours. 40 Furthermore, numbers of CD117 1 and IL-13
1 ILC2s in peripheral blood of patients with grass pollen allergy were increased during the grass pollen season compared with numbers out of the pollen season. Interestingly, out of the grass pollen season, no significant changes were observed between levels of IL-13
1 ILC2s in patients with grass pollen allergy and NACs. 41 These reports further confirm that ILC2s are involved in production of type 2 response in allergic patients.
Consistent with previous findings, 41 we observed that proportions of IL-5 1 , IL-13 1 , and dual IL-5 1 IL-13 1 ILC2s were increased in patients with SAR during the grass pollen season compared with those in NACs. Although these differences were significant, we observed heterogeneous ILC2 responses caused by donor-to-donor variation. More importantly, to address the factors involved in inhibiting type 2 responses, we show that IL-35 suppressed production of IL-5 and IL-13 cytokines by ILC2s primed with IL-25 or IL-33. This highlights the ability of IL-35 to suppress proallergic type II immune responses mediated by ILC2s. We measured the innate responses in peripheral blood as a surrogate of local mucosal response. Biopsy specimens from patients with SAR and NACs were not collected because this was beyond the scope of this particular study. However, it would be relevant to evaluate the effect IL-35 on ILC2s from nasal biopsy specimens.
This study shows that IL-35 polarizes naive T cells into iT R 35 cells in patients with SAR, which is consistent with a previously described murine study. 20 The iT R 35 cells also significantly suppressed the allergen-driven IL-4, IL-5, and IL-13 production by T H 2 cells. These suppressions were found to be IL-35 and IL-10 dependent. However, another study showed that naive T cells treated with IL-35 produce Treg cells that induce suppression exclusively through IL-35 and not through other inhibitory factors, such as TGF-b and IL-10. 20 This suggests that IL-35 contributes to immunologic tolerance by inducing iT R 35 cells after natural allergen exposure. With these observations, we further investigated the signaling pathways required for polarization of T cells with IL-35. Here we confirmed through flow cytometry that IL-35 signals through STAT1 and STAT4 after T-cell receptor stimulation, which corroborates with a previous study. 28 Further studies showed that a deficiency in one chain of the IL-35 receptor resulted in activation of only one of the STAT proteins. 28 It has been speculated that IL-12 and IFN-g, as well as IL-35, stimulate STAT1 and STAT4 to drive the T H 1 response. 28 T H 2 cells produce the conventional cytokines IL-4, IL-5, and IL-13, which are essentially responsible for induction of effector cells and induction of B cells to produce allergen-specific IgE. 42 Interestingly, IL-35 suppressed total IgE production by B cells when stimulated with CD40L, IL-4, and IL-21. However, neutralizing IL-35 antibody was able to reverse the amount of IgE-producing B cells, which can facilitate the classical T H 2 allergic immune response. 42 This study also showed that IL-4 and IL-21 act synergistically to promote production of IgE by Fig 6, B) and IL-13 (Fig 6, C) secretion was measured in the presence or absence of TSLP. D-F, Suppressive effect of IL-35 on naive T-cell proliferation (Fig 6, D) and T H 2-driven cytokine production of IL-5 (Fig 6, E) and IL-13 (Fig 6, F) . P values were determined by using the Wilcoxon matched-pairs signed-rank test: *P < .05, **P < .001, and ***P < .0001. TCM, Tissue culture medium.
B cells. Therefore it is likely that IL-35 can attenuate the allergic rhinitis response through the decrease in IgE levels and the aberrant type 2 immune responses by ILC2s and T H 2 cells.
Natural allergen-exposed epithelia release cytokines and alarmins, such as TSLP, IL-25, and IL-33, which promote ILC2s or DCs to polarize toward a T H 2 response. 43, 44 However, during AIT, DCs polarize toward an IL-10-producing Treg cell response. In particular, TSLP in patients with allergic inflammation is understood to drive DCs to promote allergen-specific naive T cells to proliferate and differentiate into T H 2 cells. 45, 46 Indeed, we have shown that IL-35 suppressed TSLP-driven DC priming of naive T-cell proliferation and differentiation into T H 2 cells, resulting in inhibition of allergen-induced IL-5 and IL-13 production. This suggests that IL-35 might be a potential therapeutic target for seasonal allergic rhinitis immunotherapy. of the effect of SLIT. However, this warrants validation in a large study, in which there would be a high likelihood of comparing nonresponders and responders in the context of efficacy (RTSS) and improvement of quality of life. IL-35 has been investigated in murine models of autoimmunity 13, 20, 47 and allergic airway inflammation. 48 Although these studies provide useful insight into the biological effect of IL-35 and iT R 35, the relevance of mouse models of lung allergic inflammation to human respiratory disease remains to be explored. Here we showed that IL-35 suppresses allergenspecific T H 2 inflammatory responses in human upper airway allergic disease. IL-35 and iT R 35 cells can be immunemonitoring markers of AIT. Furthermore, our data showed that iT R 35 cells were dysregulated in patients with SAR and that treatment with sublingual immunotherapy was associated with recovery of iT R 35 cells to numbers comparable with those observed in NACs. These findings open new avenues for developing adjunct treatment in which IL-35 could be administered either alone for its antiallergic effects or in combination with SLIT to enhance efficacy and promote durable allergen tolerance.
METHODS
Subjects: Inclusion and exclusion criteria
All allergic participants were skin prick test positive (wheal of >3mm) to Phleum pratense (Phl p) and suffered from moderate-severe grass-pollen induced symptoms for at least two years. Anti-histamine tablets and nasal sprays were excluded at least 3 days before sample collection, while topical corticosteroids were excluded for 14 days. Nonatopic control had no history of allergic symptoms and had a negative skin prick test to Phl p and to a panel of eleven common aeroallergens. Participants were excluded if they had a clinical history of other allergic diseases, asthma, chronic-obstructive pulmonary disease (COPD), recurrent acute sinusitis, chronic sinusitis, or other significant illness.
Isolation of human PBMCs
PBMCs were isolated from fresh heparinized venous blood via centrifugation over Ficoll gradients (Histopaque-1077; Sigma-Aldrich, Gillingham, United Kingdom). Heparinised blood diluted 1:1 with RPMI-1640 media (Invitrogen, Paisley, United Kingdom) was layered on 30% Ficoll-Paque Plus (GE Healthcare, Buckinghamshire, United Kingdom) density gradient and centrifuged for 25 minutes at 2200 rpm at room temperature. The PBMC layer was collected, washed and re-suspended in RPMI-1640. The cell viability was greater than 97%, as determined using trypan blue exclusion. Dendritic cells (DCs) and naive T cells were enriched from PBMCs obtained from grass pollen allergic subjects using cell enrichment kits (StemCell Technologies, Cambridge, United Kingdom).
Phenotyping of ILC2s
PBMCs (1x10 6 cells) isolated from SAR and NAC participants were stimulated for 4 hours with PMA (50 ng/mL) and Ionomycin (500 ng/mL; both from Sigma-Aldrich), in the presence of Brefeldin A (BD, Oxford, United Kingdom) for the final 3 hours of culture. Cells were surface immunostained with lineage markers-APC, CD127-PerCP-Cy5.5, CRTH2 V450 and antiFcεRI-APC. ILC2s were defined as CD127 
Effect of IL-35 on ILC2s
Lineage-negative cells comprising of ILC2s were enriched from PBMCs using lineage cell depletion kit (Miltenyi Biotec, Surrey, United Kingdom). Cells were immunostained for Lineage markers (CD3/CD14/ CD16/ CD19/CD20/CD56) (Biolegend, London, United Kingdom), CD127 (eBioscience, Hatfield, United Kingdom) and CRTH2 (Miltenyi Biotec) to allow FACS sorting of ILC2s (Lin -CD127 1 CRTH2 1 ) using BD FACSAria III (Becton Dickinson, Oxford, United Kingdom). FACS sorted ILC2s were then maintained in media containing rhIL-2 (10 ng/ mL; Peprotech, London, United Kingdom) and rhIL-7 (40 ng/mL; R&D Systems, Abingdon, United Kingdom). The effect of IL-35 on sorted ILC2s were studied over 72 hours when stimulated with rhIL-25 (50 ng/mL) or rhIL-33 (50 ng/mL; both from R&D Systems). Supernatants were then collected for the assessment of IL-5 and IL-13 production.
Effect of IL-35 on in vitro generated T H 1 and T H 2 clones
Naive T (CD4 1 CD45RA
1
) cells were polarized towards T H 1 and T H 2 clones according to previously described protocol.
E1 T H 1 clones were defined as those expressing high IFN-g and low IL-4, IL-17 and IL-22, while T H 2 clones were defined as those expressing high IL-4 and low IFN-g, IL-17, IL-22. The effect of IL-35 on CD3/CD28-mediated proliferation of in vitro generated T H 1 or T H 2 clones was measured. mRNA expression (IL-5, IL-13, IFN-g GATA-3 and Tbet) and IL-5, IL-13 and IFN-g levels were quantified.
mRNA extraction, cDNA synthesis and qRT-PCR Total RNA was extracted using RNeasy Mini Kit (Qiagen, Manchester, United Kingdom) according to the manufacturer's protocol. RNA was quantitated spectrophotometrically, and cDNA was synthesised using RevertAid First Strand cDNA Synthesis Kit (Fermentas, United Kingdom). The cDNA samples were subjected to 40 cycles of amplification on Applied Biosystems 7900HT Real-Time PCR System in an ABI PRISM 384-Well Clear Optical Reaction Plate using SYBR Green PCR master mix (Applied Biosystems, Foster City, Calif) (primer sequences listed in Table E1 ) as described previously. E2 Data was analysed on SDS 2.3 Software (Applied Biosystems). Data was normalised to housekeeping gene GAPDH and represented as fold change, as quantified using the 2 -(nnCt) method.
Intracellular staining, flow cytometry 
Multiplex assay
The secretion of 42 cytokines and chemokines following the induction of iT R 35 and 7d co-culture with or without neutralising antibodies were measured by MagPix Milliplex kit (EMD Millipore, Watford, United Kingdom) based on manufacturer's protocol. 
CD25
2 Teff cells were cocultured with irradiated APCs and stimulated with P pratense allergen in the presence of IL-35 or control. Proliferation was assessed. B and C, T H 2 (Fig E2, B) and T H 1 and IL-10 ( Fig E2, C) . P values were determined by using the Mann-Whitney U test: *P < .05, **P < .001, and ***P < .0001. 
